Abiraterone acetate was initiated immediately...Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Strong androgen receptor suppression in metastatic castration-sensitive prostate cancer can lead to aggressive radiographic progression without prostate-specific antigen elevation, underscoring the limitations of antigen-based monitoring.

2 days ago

Journal

AR (Androgen receptor)

abiraterone acetate

Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer. (PubMed, Curr Med Res Opin)

We retrospectively analyzed 148 patients with mHSPC treated with either ARPI (abiraterone, enzalutamide, or apalutamide) plus androgen deprivation therapy (ADT) (n = 98) or docetaxel plus ADT (n = 50). In this real-world cohort, ARPI-based therapy was associated with an improvement in rPFS compared with docetaxel, while OS outcomes remained comparable. In the absence of direct randomized comparisons, these findings may provide supportive real-world evidence for the clinical relevance of ARPI-based therapy as a first-line treatment option for patients with mHSPC.

2 days ago

Journal • Real-world evidence

AR (Androgen receptor)

docetaxel • enzalutamide • abiraterone acetate • apalutamide

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) (clinicaltrials.gov)

P2, N=132, Recruiting, University Health Network, Toronto | Trial completion date: Mar 2026 --> Feb 2031 | Trial primary completion date: Mar 2026 --> Feb 2031

6 days ago

Trial completion date • Trial primary completion date

enzalutamide • abiraterone acetate

CHAARTED2: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (clinicaltrials.gov)

P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Apr 2026 --> Apr 2028

7 days ago

Trial completion date

docetaxel • abiraterone acetate • prednisone • cabazitaxel

PROPEL: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)

P3, N=895, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2026 --> Feb 2027

8 days ago

Trial completion date

HRD (Homologous Recombination Deficiency)

Lynparza (olaparib) • abiraterone acetate

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (clinicaltrials.gov)

P3, N=5000, Not yet recruiting, Exelixis

8 days ago

New P3 trial

Opdivo (nivolumab) • Tecentriq (atezolizumab) • enzalutamide • Cabometyx (cabozantinib tablet) • abiraterone acetate • prednisone • zanzalintinib (XL092)

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)

P1/2, N=212, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

8 days ago

Enrollment open

enzalutamide • abiraterone acetate • MHB088C

13d

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (clinicaltrials.gov)

P3, N=670, Recruiting, AstraZeneca

13 days ago

New P3 trial

FOLH1 positive

enzalutamide • abiraterone acetate • Nubeqa (darolutamide) • cabazitaxel • apalutamide • Xofigo (radium Ra-223 dichloride) • AiRuiEn (rezvilutamide) • FPI-2265 • prednisolone

14d

EvoPAR-PR01: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (clinicaltrials.gov)

P3, N=1889, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2028 --> Sep 2027

14 days ago

Enrollment closed • Trial primary completion date

BRCA (Breast cancer early onset)

BRCA mutation

enzalutamide • abiraterone acetate • Nubeqa (darolutamide) • saruparib (AZD5305)

15d

A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR (PubMed, Hinyokika Kiyo)

Five years later, progression to castration-resistant prostate cancer was confirmed, and abiraterone treatment was started...Treatment with docetaxel was initiated...The patient was started on olaparib, a poly (ADP-ribose) polymerase inhibitor. To date, his PSA level has remained below 0.001 ng/ml. He has been taking the medication for more than 42 months without any side effects, and imaging studies have consistently shown a complete response.

15 days ago

Journal • BRCA Biomarker • PARP Biomarker

BRCA2 (Breast cancer 2, early onset)

FoundationOne® CDx

Lynparza (olaparib) • docetaxel • abiraterone acetate

15d

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone (clinicaltrials.gov)

P2, N=61, Completed, Masonic Cancer Center, University of Minnesota | Active, not recruiting --> Completed | N=22 --> 61

15 days ago

Trial completion • Enrollment change

carboplatin • abiraterone acetate • prednisone • cabazitaxel

19d

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer (clinicaltrials.gov)

P2, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Aug 2028 --> May 2026

19 days ago

Trial completion • Trial completion date

EGFR (Epidermal growth factor receptor)

enzalutamide • abiraterone acetate • prednisone • goserelin acetate